Neoadjuvant treatment in non-small cell lung cancer:New perspectives with the incorporation of immunotherapy  

作　　者：Carlos Aguado Luis Chara Mónica Antonanzas Jose Maria Matilla Gonzalez Unai Jiménez Raul Hernanz Xabier Mielgo-Rubio Juan Carlos Trujillo-Reyes Felipe Counago 

机构地区：[1]Department of Medical Oncology,Hospital Clínico Universitario San Carlos,Madrid 28040,Spain [2]Department of Medical Oncology,Hospital Universitario de Guadalajara,Guadalajara 19002,Spain [3]Department of Thoracic Surgery,Hospital Clínico Universitario de Valladolid,Valladolid 47005,Spain [4]Department of Thoracic Surgery,Hospital Universitario Cruces,Barakaldo,Bizkaia 48903,Basque Country,Spain [5]Department of Radiation Oncology,Hospital Universitario Ramón y Cajal,Madrid 28034,Spain [6]Department of Medical Oncology,Hospital Universitario Fundación Alcorcón,Alcorcón 28922,Madrid,Spain [7]Department of Thoracic Surgery,Hospital de la Santa Creu I Sant Pau,Barcelona 08029,Catalonia,Spain [8]Department of Surgery,Universitat Autonoma de Barcelona,Barcelona 08029,Catalonia,Spain [9]Department of Radiation Oncology,Hospital Universitario Quirónsalud Madrid,Pozuelo de Alarcón 28223,Madrid,Spain [10]Department of Radiation Oncology,Hospital La Luz,Madrid 28003,Spain [11]Medicine Department,School of Biomedical Sciences,Universidad Europea de Madrid,Villaviciosa de Odón 28670,Madrid,Spain

出　　处：《World Journal of Clinical Oncology》2022年第5期314-322,共9页世界临床肿瘤学杂志（英文版）

摘　　要：The aim of neoadjuvant treatment in non-small cell lung cancer(NSCLC)is to eliminate micrometastatic disease to facilitate surgical resection.Neoadjuvant chemotherapy(ChT)in localised NSCLC has numerous advantages over other therapeutic modalities and is considered standard treatment in resectable disease.Treatment with immune checkpoint inhibitors(ICI)improves long-term survival in advanced disease and has a better toxicity profile than conventional therapies.These immunotherapy agents(anti-PD1/PD-L1),administered with or without ChT,are currently being evaluated in the preoperative setting,with initial results showing better pathological response rates and more long-term benefits.Importantly,these drugs do not appear to increase the rate of severe adverse effects and/or postoperative complications.However,several questions still need to be resolved,including the identification of predictive biomarkers;comparative studies of immunotherapy alone vs combined treatment with ChT and/or radiotherapy;the optimal duration of treatment;the timing of surgery;the need for adjuvant treatment;appropriate radiologic evaluation and mediastinal staging;and the correlation between pathological response and survival outcomes.Here we review the current evidence for immunotherapy from a multidisciplinary perspective and discuss current and future controversies.

关 键 词：Non-small cell lung cancer NEOADJUVANT Immune checkpoint inhibitors IMMUNOTHERAPY Anti-PD1 Anti-PD-L1 Complete pathological response 

分 类 号：R734.2[医药卫生—肿瘤]